Menu
Search
|

Menu

Close
X

Tonghua Dongbao Pharmaceutical Co Ltd 600867.SS (Shanghai Stock Exchange)

14.51 CNY
+0.12 (+0.83%)
As of 7:00 AM GMT
chart
Previous Close 14.39
Open 14.32
Volume 14,731,227
3m Avg Volume 23,368,719
Today’s High 14.69
Today’s Low 13.83
52 Week High 27.51
52 Week Low 11.72
Shares Outstanding (mil) 1,711.30
Market Capitalization (mil) 33,028.02
Forward P/E 44.04
Dividend (Yield %) 0.17 ( 0.86 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.53 Mean rating from 17 analysts

KEY STATS

Revenue (mm, CNY)
FY18
2,009
FY17
2,545
FY16
2,040
FY15
1,669
EPS (CNY)
FY18
0.335
FY17
0.408
FY16
0.325
FY15
0.251
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
44.04
33.64
Price to Sales (TTM)
vs sector
14.17
5.95
Price to Book (MRQ)
vs sector
8.10
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
10.53
17.74
LT Debt to Equity (MRQ)
vs sector
1.48
13.15
Return on Investment (TTM)
vs sector
21.13
14.22
Return on Equity (TTM)
vs sector
22.29
15.99

EXECUTIVE LEADERSHIP

Yikui Li
Chairman of the Board, Since 2007
Salary: --
Bonus: --
Junye Wang
Chief Accounting Officer, Secretary of the Board, Director, Since
Salary: --
Bonus: --
Cong Li
General Manager, Director, Since 2007
Salary: --
Bonus: --
Chunsheng Leng
Deputy General Manager, Director, Since 2007
Salary: --
Bonus: --
Hong Chen
Deputy General Manager, Chief Engineer, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Dongbao New Village, Tonghua Cou
TONGHUA   JLN   134123

Phone: +86435.5088025
Site: www.thdb.com

TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.

SPONSORED STORIES